Results 191 to 200 of about 470,609 (301)

Advanced nanotherapeutics for combating ocular infections: Rational design, antimicrobial mechanisms, and therapeutic breakthroughs

BMEMat, EarlyView.
Nanomaterials revolutionize ocular infection treatment by enabling targeted drug delivery and enhanced antimicrobial efficacy against resistant pathogens. This review systematically explores their rational design, multimodal mechanisms, and translational potential for next‐generation anti‐infective therapies.
Yujia Liu, Xuetian Wen, Yue Tan, Rui Zeng, Yijuan Zhang, Tong Lin, Lan Gong, Zichao Luo   +7 more
wiley   +1 more source

Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk. [PDF]

Vaccine
Wong JM, Acevedo PK, Whitehead S, Durbin A, DeSale H, Jones FK, Medina FA, Rovira-Diaz E, Prutzman K, Leao IC, Wang T, Desilva A, Harris E, Katzelnick L, Salje H, Weiskopf D, Adams LE, Paz-Bailey G.   +17 more
europepmc   +1 more source

Programmable three‐state nanoreactor for spatiotemporally controlled tumor therapy

BMEMat, EarlyView.
The OMVs are shielded with a biocompatible Da–Ca shell, which prolongs its circulation period and promotes intratumoral accumulation. Importantly, the biocompatible Da–Ca shell can be controllably disintegrated in tumor microenvironment by using laser irradiation, generating in situ hyperthermia and releasing Ca2+.
Guihong Lu, Peng Ye, Xiaoyan Li, Ke Ma, Chengliang Lyu, Kai Zhang, Ran Luo, Yang Ji, Shiqi Mei, Fan Zhang, Jinxie Zhang, Lin Mei, Hui Tan   +12 more
wiley   +1 more source

Contributing Factors to Infectious Disease Risk and Vaccine Strategy Optimization in Cardiac Surgery Patients. [PDF]

Vaccines (Basel)
Tokarczyk-Kloc M, Ciecierska J, Marguła R, Herbetko K, Shmorhun B, Szenborn L, Sokolski M, Ludwikowska KM.   +7 more
europepmc   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

Vaccination in immunocompetent and immunosuppressed youth with special health care needs during healthcare transition. [PDF]

Clinics (Sao Paulo)
Yarshell FC, Doria CR, Ferrer APS, Delgado AF, Fonseca CB, Souza DC, Sampaio PHP, Pereira MFB, Aikawa NE, Silva CA.   +9 more
europepmc   +1 more source

Beyond antimicrobials: Ecological nano‐strategies for rebalancing dysbiotic oral microbial homeostasis

BMEMat, EarlyView.
Oral microbial homeostasis, a dynamic host‐microbe balance, is vital in infectious diseases. Conventional antibiotics often disrupt this homeostasis, spurring interest in nanomaterials for oral microbial homeostasis rebalancing. This review outlines nanomaterial strategies across three ecological levels (population/community, ecosystem, and cross ...
Chen Hu, Aohan Luan, Yujun Yang, Linlin Wang, Huilin Wang, Ning Wang, Guixin He, Yajie Yang, Rabiya Noor, Jawad Hussain, Longquan Shao   +10 more
wiley   +1 more source

Tattooing and immune response: A mouse model too far from clinical reality. [PDF]

Proc Natl Acad Sci U S A
Kluger N.
europepmc   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, Matthijs Moerland, Jacobus J. Bosch   +11 more
wiley   +1 more source

Genotype II Live-Attenuated ASFV Vaccine Bearing 24 Genes Deletion in 3 Independent Regions Is Able to Provide Complete Protection Against Homologous Lethal Challenge. [PDF]

FASEB J
Xu F, Dang W, Du Y, Li T, Liu H, Shi Z, Tian H, He J, Zheng H.   +8 more
europepmc   +1 more source